Alkol ve Madde Kullanım Bozukluklarında Acil Durumlara Yaklaşım
Özet
Alkol ve madde kullanım bozuklukları (AMKB) ile ilişkili acil durumlar, intoksikasyonlar, yoksunluk sendromları, psikotik semptomlar ve deliryum gibi tablolarla acil servislere sıklıkla başvurulan önemli sağlık sorunlarıdır. Alkol intoksikasyonunda bilişsel yetilerde bozulma, ajitasyon ve koordinasyon kaybı görülürken; ileri seviyelerde koma ve solunum depresyonu hayati risk oluşturur. Tedavide solunumun korunması, dekstroz öncesi parenteral tiamin desteği ve ajitasyon için haloperidol kullanımı öne çıkar. Alkol yoksunluk sendromu (AYS) ise titreme, otonomik hiperaktivite, nöbet ve ölümcül olabilen Deliryum Tremens (DT) ile karakterizedir; takibinde CIWA-Ar ölçeği, tedavisinde ise altın standart olan benzodiazepinler ve destekleyici vitamin replasmanları kullanılır. Sentetik kannabinoid intoksikasyonları, THC'den daha güçlü reseptör agonistleri olmaları sebebiyle şiddetli taşikardi, psikotik belirtiler ve akut böbrek yetmezliği gibi öngörülemeyen kardiyovasküler ve nöropsikiyatrik tablolara yol açar; tedavisinde benzodiazepin ve antipsikotikler tercih edilir. Opioid intoksikasyonlarında en kritik bulgular solunum depresyonu, miyozis ve koma olup, acil müdahalede kısa etkili opioid antagonisti nalokson kullanılır. Opioid yoksunluğunda ise COWS ölçeği ile izlem yapılırken buprenorfin, metadon gibi parsiyel agonist/agonist tedavileri veya klonidin gibi non-opioid ajanlar semptomatik rahatlama sağlar. Tüm bu tablolarda hızlı ve doğru ayırıcı tanı ile multidisipliner yaklaşımlar hayat kurtarıcıdır.
Alcohol and substance use disorders (ASUD) are significant health problems frequently presenting to emergency departments with conditions such as intoxications, withdrawal syndromes, psychotic symptoms, and delirium. Alcohol intoxication manifests with cognitive impairment, agitation, and loss of coordination, while advanced levels pose fatal risks like coma and respiratory depression. Treatment emphasizes respiratory protection, parenteral thiamine support before dextrose, and haloperidol for agitation. Alcohol withdrawal syndrome (AWS) is characterized by tremors, autonomic hyperactivity, seizures, and potentially fatal Delirium Tremens (DT); the CIWA-Ar scale is used for monitoring, while benzodiazepines, the gold standard, and supportive vitamin replacements are used for treatment. Synthetic cannabinoid intoxications lead to unpredictable cardiovascular and neuropsychiatric conditions such as severe tachycardia, psychotic symptoms, and acute kidney injury due to being more potent receptor agonists than THC, and are treated with benzodiazepines and antipsychotics. The most critical findings in opioid intoxications are respiratory depression, miosis, and coma, and the short-acting opioid antagonist naloxone is utilized in emergency intervention. Opioid withdrawal is monitored using the COWS scale, and symptomatic relief is provided through partial agonist/agonist treatments like buprenorphine and methadone, or non-opioid agents such as clonidine. In all these clinical presentations, rapid and accurate differential diagnosis along with multidisciplinary approaches are life-saving.
Referanslar
Wittmann C, Donovan AL, Nisavic M. Alcohol and Sedative Use Disorders and Related Emergencies. In: Donovan AL, Bird SA (eds.) Substance use and the acute psychiatric patient : emergency management. Springer International Publishing; 2019. p. 27–50.
Şengül C. Alkol İntoksikasyonu ve Yoksunluğu Tedavisi. In: Evren C, Ögel K, Uluğ B (eds.) Alkol Madde Bağımlılığı Tanı ve Tedavi El Kitabı. Ankara: Türkiye Psikiyatri Derneği; 2012. p. 77-90.
Saunders JB, Conigrave KM, Latt NC, et al. Addiction medicine. New York: Oxford University Press; 2016.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association; 2013.
Nace E. Substances of Abuse: Alcohol. In: Mack AH, Brady KT, Miller SI, Frances RJ (eds.) Clinical Textbook of Addictive Disoders. New York: The Guilford Press; 2016. p. 73–90.
Attilia F, Perciballi R, Rotondo C, et al. Alcohol withdrawal syndrome: Diagnostic and therapeutic methods. Rivista di Psichiatria. 2018;53(3): 118–122. doi:10.1708/2925.29413
Kattimani S, Bharadwaj B. Clinical management of alcohol withdrawal: A systematic review. Industrial Psychiatry Journal. 2013;22(2): 100. doi:10.4103/0972-6748.132914
Pribék IK, Kovács I, Kádár BK, et al. Evaluation of the course and treatment of Alcohol Withdrawal Syndrome with the Clinical Institute Withdrawal Assessment for Alcohol – Revised: A systematic review-based meta-analysis. Drug and Alcohol Dependence. 2021;220: 108536. doi:10.1016/J.DRUGALCDEP.2021.108536
Evren C, Dalbudak E. Alkol ve Madde Kullanım Bozukluklarında Acil Durumlara Yaklaşım. In: Evren C (ed.) Alkol ve Madde Kullanım Bozuklukları Temel Başvuru Kitabı. Ankara: Türkiye Psikiyatri Derneği; 2019. p. 13–33.
Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). British journal of addiction. 1989;84(11): 1353–1357. doi:10.1111/J.1360-0443.1989.TB00737.X
Bakhla AK, Khess CRJ, Verma V, et al. Factor Structure of CIWA-Ar in Alcohol Withdrawal. Journal of Addiction. 2014;2014: 1–7. doi:10.1155/2014/745839
Perry EC. Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs. 2014;28(5): 401–410.
Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database of Systematic Reviews. 2011;(6).
Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ. 1999;160(5): 649–655.
Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal. The New England journal of medicine. 2003;348(18): 1786–1795. doi:10.1056/NEJMRA020617
Maldonado JR, Sher Y, Ashouri JF, et al. The ‘Prediction of Alcohol Withdrawal Severity Scale’ (PAWSS): Systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol. 2014;48(4): 375–390. doi:10.1016/J.ALCOHOL.2014.01.004
Weintraub SJ. Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal. CNS drugs. 2017;31(2): 87–95. doi:10.1007/S40263-016-0403-Y
Ntais C, Pakos E, Kyzas P, et al. Benzodiazepines for alcohol withdrawal. The Cochrane database of systematic reviews. 2005;168(3): 2896–2899. doi:10.1002/14651858.CD005063.PUB2
Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). The New England journal of medicine. 2014;371(22): 2109–2113. doi:10.1056/NEJMRA1407298
Monte AA, Calello DP, Gerona RR, et al. Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study. Journal of medical toxicology. 2017;13(2): 146–152. doi:10.1007/S13181-017-0605-9
Evren C, Bozkurt M. Synthetic cannabinoids: Crisis of the decade. Dusunen Adam - The Journal of Psychiatry and Neurological Sciences. 2013;26(1): 1–11. doi:10.5350/DAJPN20132601001
Alves VL, Gonçalves JL, Aguiar J, et al. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. Critical reviews in toxicology. 2020;50(5): 359–382. doi:10.1080/10408444.2020.1762539
Sidelnik SA, Benzer TI. Cannabis Use Disorders and Related Emergencies. In: Donovan AL, Bird SA (eds.) Substance use and the acute psychiatric patient : emergency management. Springer International Publishing; 2019. p. 69–81.
Rao V, Ward EN. Opioid Use Disorders and Related Emergencies. In: Donovan AL, Bird SA (eds.) Substance use and the acute psychiatric patient : emergency management. Springer International Publishing; 2019. p. 3–25.
Öztürk Sarıkaya Ö. Opioid İntoksikasyonlarına Yaklaşım ve Tedavi. In: Evren C (ed.) Alkol ve Madde Kullanım Bozuklukları Temel Başvuru Kitabı. Ankara: Türkiye Psikiyatri Derneği; 2019. p. 168–175.
Fareed A, Stout S, Casarella J, et al. Illicit Opioid Intoxication: Diagnosis and Treatment. Substance Abuse: Research and Treatment. 2011;5(1): 17. doi:10.4137/SART.S7090
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Therapeutic advances in drug safety. 2018;9(1): 63–88. doi:10.1177/2042098617744161
Altınyazar V. Psikiyatride Sık Karşılaşılan Toksik Sendromlar. Psikiyatride Güncel Yaklaşımlar. 2010;2(4): 532–571.
Altıntoprak AE, Evren EC, Aydemir Ö, et al. Klinik Opiyat Yoksunluk Ölçeği (Clinical Opiate Withdrawal Scale-COWS) Türkçe Sürümünün Güvenilirliği ve Geçerliliği. Nöro Psikiyatri Arşivi. Turk Noropsikiyatri Dernegi; 2015; 52: 89-94. doi:10.4274/NPA.Y7169
Gorodetzky CW, Walsh SL, Martin PR, et al. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug and alcohol dependence. 2017;176: 79–88. doi:10.1016/J.DRUGALCDEP.2017.02.020
